NCT07406542 2026-02-12A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast CancerCSPC Megalith Biopharmaceutical Co.,Ltd.Phase 3 Not yet recruiting400 enrolled